Gastrointestinal Cancer | Topics

 
Oncology Peer Review On-The-Go: Tanios Bekaii-Saab, MD, and Colleagues Discuss GOZILA Platform for CRC
May 17, 2022

Tanios Bekaii-Saab, MD, details the GOZILA platform for colorectal cancer with experts Kristen Ciombor, MD, MSCI, and John Strickler, MD.

Oncology Peer Review On-The-Go: Tanios Bekaii-Saab, MD, Talks COLOMATE Platform in CRC With Experts
May 10, 2022

Tanios Bekaii-Saab, MD, sits with Kristen Ciombor, MD, MSCI, and John Strickler, MD, to examine the COLOMATE platform for patients with colorectal cancer.

Sam Klempner, MD, Looks at Broad Use of ctDNA in Oncology
May 05, 2022

Sam Klempner, MD, spoke about how clinicians exploring use of ctDNA in gastrointestinal cancers may inform their research with results from other tumor types.

FDA Grants Priority Review to Durvalumab Plus Chemo in Locally Advanced or Metastatic Biliary Tract Cancer
May 04, 2022

The results of the phase 3 TOPAZ-1 trial led to the priority review of durvalumab plus chemotherapy in patients with locally advanced biliary tract cancer.

CMG901 Granted Fast Track Designation by FDA in Unresectable or Metastatic Relapsed/Refractory Gastric and GEJ Cancer
April 27, 2022

Patients with unresectable or metastatic gastric or gastroesophageal junction cancer that is relapsed/refractory following other approved therapies may benefit from treatment with single-agent CMG901, which was granted fast track designation by the FDA.

Sam Klempner, MD, Talks ctDNA for Nonmetastatic Gastric and Esophageal Cancers
April 27, 2022

Sam Klempner, MD, spoke about clinical management and ctDNA for gastrointestinal cancers.

Sam Klempner, MD, Discusses Minimal Residual Disease in Gastrointestinal Cancers
April 18, 2022

Sam Klempner, MD, spoke about the importance of expanding minimal residual disease platforms for patients with gastrointestinal cancers.

Encouraging pCR Reported With Pembrolizumab Plus Chemo for Resectable Gastric, GEJ Adenocarcinoma
April 11, 2022

Patients with resectable gastric and gastroesophageal junction adenocarcinoma experienced good pathologic complete response with standard of care chemotherapy and perioperative/adjuvant pembrolizumab.

Gastrointestinal Cancers Exhibit Clear Benefit With Addition of Nivolumab to Chemotherapy, Regardless of TMB Status
April 11, 2022

Results of CheckMate 649 trial show consistently improved outcomes across advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma when nivolumab is administered in combination with chemotherapy.

Investigators Identify Significant Racial Disparities in Surgical Care for Cancers of the GI Tract
April 08, 2022

Black patients were reported to be significantly less likely to receive standard of care surgical treatment for cancer of the gastrointestinal tract compared with White patients.